David Grainger

David Grainger Net Worth

David Grainger is an entrepreneur and wildlife artist who, along with his wife Janice Stone, founded The Guild of Automotive Restorers in 1991. The Guild has since been featured on TV, radio, and in print around the world. David's hobbies include flying planes, riding horses, and racing boats, and The Guild was established to give him the resources to pursue these costly endeavors. He has also worked with injured birds, trained large cats, interacted with reptiles, and been a professional diver with a history of working with sharks. His artwork has been published in the Globe and Mail, National Post, and Octane magazine. At age 64, David shows no signs of slowing down.

Age, Biography and Wiki

Birth Day October 12, 1966
Age 57 YEARS OLD
Alma mater Cambridge University
Occupation venture capitalist, medicxi, biotechnology executive, Methuselah Health Ltd., blogger

💰 Net worth

David Grainger's net worth is projected to range between $100,000 and $1 million by 2024. Known as an entrepreneur and wildlife artist, Grainger, in collaboration with his wife Janice Stone, embarked on their entrepreneurial journey by establishing The Guild of Automotive Restorers in 1991. This enterprise gained recognition as a renowned institution specializing in the restoration and preservation of antique automobiles. With their passion for automotive artistry and dedication to craftsmanship, Grainger and Stone have garnered success over the years. As a wildlife artist, Grainger's artistic talents have also contributed to his entrepreneurial endeavors, further adding to his net worth.

Biography/Timeline

1989

Reared in England, Grainger graduated with degree in Natural Sciences (Biochemistry) from Cambridge University in 1989, and a PhD in Vascular Cell Biology from the same institution in 1992.

1997

After receiving his PhD, Grainger undertook post-doctoral research in the British Heart Foundation Smooth Muscle Cell laboratory at Cambridge University. Following publications in Nature and elsewhere setting out his Protective Cytokine Hypothesis explaining the role of the cytokine TGF-beta 1 in the cardiovascular system, Grainger was appointed principal investigator in the Department of Medicine at his alma mater, Cambridge University, in 1997.

2001

While at Cambridge University, Grainger founded life sciences companies including FingerPrint Diagnostics (2001), and Funxional Therapeutics (2005). FingerPrint Diagnostics merged with SmartBead Technologies to form Pronostics, a molecular diagnostics company, in 2006. Funxional Therapeutics, based on an anti-inflammatory drug candidate spun-out from Grainger's Cambridge University lab, became an Index Ventures portfolio company where Grainger also served as chief scientific officer until it was sold to Boehringer Ingelheim in 2012.

2012

Grainger joined Index Ventures in 2012, and a Blogger on topics related to the pharmaceutical industry under the pen name “DrugBaron”. where he was involved with funding and advising a variety of companies, including XO1, a biotech company developing an anticoagulant, where he served as chairman and interim CEO before it was sold to Johnson & Johnson He co-founded medicxi in February 2016 with fellow former Index Ventures partners Francesco De Rubertis, Kevin Johnson and Michele Ollier.

2019

He was formerly with Index Ventures, an international venture capital firm with offices in London, Geneva and San Francisco, in the firm’s life sciences practice. He also writes for Forbes.com on topics related to the pharmaceutical industry.

Some David Grainger images

About the author

Lisa Scholfield

As a Senior Writer at Famous Net Worth, I spearhead an exceptional team dedicated to uncovering and sharing the stories of pioneering individuals. My passion for unearthing untold narratives drives me to delve deep into the essence of each subject, bringing forth a unique blend of factual accuracy and narrative allure. In orchestrating the editorial workflow, I am deeply involved in every step—from initial research to the final touches of publishing, ensuring each biography not only informs but also engages and inspires our readership.